Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Published loading...Updated

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics aims to fund clinical development of gene therapies TN-201 and TN-401 with $60 million raised from sale of 50 million units at $1.20 each.

Summary by Hastings Tribune
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced…

6 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Friday, December 12, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal